All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testing

Feb 11, 2021
Share:

The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.1 HDP-101 is being assessed for the treatment of patients with multiple myeloma (MM). This agent uses amanitin, derived from Amanita phalloides (death cap mushroom), as the cytotoxic agent in an antibody-targeted conjugate.

The phase I study will evaluate the maximum tolerated dose of HDP-101 by performing a dose escalation study. Then the data from this section will be taken forward into the phase IIa portion which will examine the anticancer efficacy of HDP-101. In the phase IIa trial, patients will be stratified upon their 17p deletion status as this biomarker has been shown to indicate increased sensitivity to amanitin. The expectation is that the first patient will be enrolled and dosed in the second quarter of 2021. The aim will be to enroll 30 patients in the phase I portion and 36 in the phase IIa section.

Preclinical studies have shown positive results with low dose HDP-101 in mouse xenograft models producing durable complete remissions after one intravenous administration. The mechanism of action of this antibody–drug conjugate is thought to involve the inhibition of RNA polymerase II, leading to the initiation of apoptosis in the affected cell. Therefore, as low-level transcription occurs in even dormant cells, HDP-101 was effective at killing active and resting MM cells.2

  1. PipelineReview.com. FDA allows Heidelberg Pharma to start a phase I/IIa clinical trial with ATAC candidate HDP-101. https://pipelinereview.com/index.php/2021020477353/Antibodies/FDA-Allows-Heidelberg-Pharma-to-Start-a-Phase-I/IIa-Clinical-Trial-with-ATAC-Candidate-HDP-101.html. Published Feb 4, 2020. Accessed Feb 5, 2020.
  2. Figueroa-Vazquez V, Ko J, Breunig C, et al. HDP-101, an anti-BCMA antibody–drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20(2):367-378; DOI: 1158/1535-7163.MCT-20-0287